Entries by arcticnovartis

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
arcticnovartis
Tue, 11/04/2025 – 07:19

Read more about New Novartis data at ASN Kidney Week and AHA Scientific Sessions demon…

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
arcticnovartis
Wed, 10/29/2025 – 15:34

Read more about Novartis ianalumab first drug to reduce disease activity and patient burden in…

Novartis completes acquisition of Tourmaline Bio

Novartis completes acquisition of Tourmaline Bio
arcticnovartis
Tue, 10/28/2025 – 15:04

Read more about Novartis completes acquisition of Tourmaline Bio

Basel, October 28, 2025 – Novartis today announced that it has successfully co…

Novartis announces expiration of Tourmaline Bio tender offer 

Novartis announces expiration of Tourmaline Bio tender offer 
arcticnovartis
Tue, 10/28/2025 – 07:28

Read more about Novartis announces expiration of Tourmaline Bio tender offer 

Basel, October 28 2025 – Novartis tod…

Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt

Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt
arcticnovartis
Tue, 10/28/2025 – 07:02

Read more about Nov…

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
arcticnovartis
Tue, 10/28/2025 – 07:02

Read more about Novartis delivers solid sales and core operating income growth wi…

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
arcticnovartis
Sun, 10/26/2025 – 18:04

Read more about Novartis agrees to acquire Avidity Biosciences, an innovat…

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
arcticnovartis
Sun, 10/26/2025 – 18:03

Read more about Novartis agrees to acquire Avidity Biosciences, an innovat…

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
arcticnovartis
Sat, 10/25/2025 – 17:04

Read more about Novartis showcases significant immunology advancements in ACR congress with …

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
arcticnovartis
Sat, 10/25/2025 – 17:04

Read more about Novartis showcases significant immunology advancements in ACR congress with …